Oppenheimer upgraded Enhabit (EHAB) to Outperform from Perform with a $14 price target The firm believes the post-acute care group is benefiting from “major tailwinds,” including strong demand, a more stable regulatory environment, and improving labor trends. Enhabit is positioned to benefit from an improved reimbursement outlook, the analyst tells investors in a research note. In addition, Oppenheimer says the company’s operational initiatives should drive the business going forward.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHAB:
- Enhabit upgraded to Outperform from Perform at Oppenheimer
- Enhabit upgraded to Buy from Hold at TD Cowen
- Enhabit upgraded to Buy from Neutral at UBS
- Enhabit: Improved Regulatory Outlook, Discounted Valuation, and Offensive Capital Deployment Support Buy Rating and Higher $12 Target
- Enhabit initiated with a Hold at Truist